To excise or not: impact of MelaFind on German dermatologists’ decisions to biopsy atypical lesions
Axel Hauschild(University Hospital Schleswig-Holstein), Dina Gutkowicz–Krusin(STRATA Skin Sciences (United States)), Jeff Goldsmith(Columbia University), Daniel O. Scharfstein(University of Utah), Hadley C. King(Cornell University), Suephy C. Chen(Thomas Jefferson University), Andreas Blum(Klinikum Konstanz), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel)
Cited by 46
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A National Evaluation of the Effect of Trauma-Center Care on Mortality
|New England Journal of Medicine|2006|2.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k